Previous Close | 1.2500 |
Open | 1.2900 |
Bid | 1.1300 x 2200 |
Ask | 1.1700 x 1000 |
Day's Range | 1.0400 - 1.3400 |
52 Week Range | 1.0400 - 49.8000 |
Volume | |
Avg. Volume | 379,429 |
Market Cap | 7.043M |
Beta (5Y Monthly) | 2.32 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -12.9000 |
Earnings Date | Nov 14, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 120.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for SEEL
Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has priced its underwritten public offering of 1,781,934 shares of its common stock, pre-funded warrants to purchase up to 2,422,612 shares of its common stock and accompanying common warrants to purchase up to 4,204,546 shares of its common stock. Each share of common stock and acco
Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase shares of its common stock in lieu thereof) and accompanying common warrants to purchase shares of its common stock. Seelos also intends to grant the underwriters a 45-day
Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that SLS-002 (intranasal racemic ketamine) has been selected for inclusion in an adaptive platform trial to evaluate treatments for post-traumatic stress disorder (PTSD) in active-duty service members and veterans. The trial is funded by the U.S. Department of Defense's (DOD) Defense Health